Genmab A/S
(WBO:GMAB)
€
245
-1.8 (-0.73%)
Market Cap: 15.71 Bil
Enterprise Value: 11.88 Bil
PE Ratio: 22.03
PB Ratio: 3.66
GF Score: 90/100 
Q1 2024 Genmab A/S Earnings Call TranscriptMay 02, 2024€259.4 (-1.33%)Earnings- Genmab A/S Annual Shareholders Meeting TranscriptMar 13, 2024
- Q4 2023 Genmab A/S Earnings Call TranscriptFeb 14, 2024€257.2 (+3.54%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 12, 2023
- Q3 2023 Genmab A/S Earnings Call TranscriptNov 07, 2023€276.1 (+3.02%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Half Year 2023 Genmab A/S Earnings Call TranscriptAug 03, 2023€353.9 (-1.72%)Earnings
- Genmab A/S at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Genmab A/S Earnings Call TranscriptMay 10, 2023€361.7 (-0.17%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2023
- Q4 2022 Genmab A/S Earnings Call TranscriptFeb 22, 2023€371.1Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 13, 2022
- Q3 2022 Genmab A/S Earnings Call TranscriptNov 09, 2022€396Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 Genmab A/S Earnings Call TranscriptAug 10, 2022€346.1 (+0.32%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Q1 2022 Genmab A/S Earnings Call TranscriptMay 11, 2022€275.2 (-1.50%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2022
- Q4 2021 Genmab A/S Earnings Call TranscriptFeb 16, 2022€299.1 (+0.17%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Genmab A/S Virtual R&D Update and ASH Data Review TranscriptDec 14, 2021
- Q3 2021 Genmab A/S Earnings Call TranscriptNov 10, 2021€375 (-4.07%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Genmab A/S Earnings Call TranscriptAug 11, 2021€381.5 (-1.42%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Q1 2021 Genmab A/S Earnings Call TranscriptMay 05, 2021€300.2 (+0.67%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptApr 13, 2021
- Q4 2020 Genmab A/S Earnings Call TranscriptFeb 23, 2021€299.1 (-5.41%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Genmab A/S Virtual 2020 ASH Data Review Meeting TranscriptDec 08, 2020
- Genmab A/S Virtual Capital Markets Day TranscriptNov 13, 2020
- Q3 2020 Genmab A/S Earnings Call TranscriptNov 04, 2020€318.1 (+8.90%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Q2 2020 Genmab A/S Earnings Call TranscriptAug 12, 2020Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Genmab A/S to Discuss Broad Oncology Collaboration with Abbvie Inc Call TranscriptJun 10, 2020
- Q1 2020 Genmab A/S Earnings Call TranscriptMay 06, 2020Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Genmab A/S at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 18, 2020
- Q4 2019 Genmab A/S Earnings Call TranscriptFeb 19, 2020Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Genmab A/S 2019 R&D Update and ASH Data Review Meeting TranscriptDec 10, 2019
- Q3 2019 Genmab A/S Earnings Call TranscriptNov 06, 2019Earnings
- Q2 2019 Genmab A/S Earnings Call TranscriptAug 14, 2019Earnings
- Q1 2019 Genmab A/S Earnings Call TranscriptMay 08, 2019Earnings
- Q4 2018 Genmab A/S Earnings Call TranscriptFeb 20, 2019Earnings
Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021 / 12:00PM GMT
Release Date Price:
€383.6
(-1.16%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director
Everybody, I'm Matthew Harrison, one of the Biotech analyst here at Morgan Stanley. Very pleased to have you join day 1 of our virtual conference and pleased to get started off with Genmab. And Jan van de Winkel, the CEO and President from Genmab. Just quickly before we start, I just need to read a disclosure statement.
Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. And with that, Jan, I'm going to turn it over to you to make a couple of minutes of opening remarks, and then we can jump into the Q&A.
Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO
/-- -
Thanks, Matthew. Good morning, everybody. We are delighted to be at this meeting. So Genmab had a very strong first half of the year and is on track, I think, for an excellent second half. We had,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers